The FDA is expected to decide on treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis.

The REMS program for the ERA drug class was established due to the risk of embryofetal toxicity seen from animal studies.

The lawsuit was prompted by several recent HHS actions the plaintiffs noted were “designed to mislead, confuse, and gradually desensitize the public to anti-vaccine and anti-science rhetoric.” ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

An analysis of pharmacokinetic data showed ET-600 was bioequivalent to an FDA-approved oral desmopressin product.

The FDA considers the recall “terminated,” meaning it’s no longer active. But officials are urging parents to check their shelves just in case.

The reconstituted panel has not discussed RSV vaccination again and has already caused concern among doctors by questioning proven science around flu vaccines and childhood immunizations.

HealthDay News — Patients undergoing retinal detachment (RD) repair with concomitant cannabis use have a lower risk for subsequent proliferative vitreoretinopathy (PVR) and requiring subsequent ...

HealthDay News — The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) are compared in a systematic literature review and network ...

Trump administration's denial of visas for citizens of certain countries preventing medical residents from filling critical positions in US hospitals.